These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1451723)

  • 1. Pharmacokinetics of carteolol in patients with impaired renal function.
    Amemiya M; Tabei K; Furuya H; Sakairi Y; Asano Y
    Eur J Clin Pharmacol; 1992; 43(4):417-21. PubMed ID: 1451723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of carteolol in relation to renal function.
    Hasenfuss G; Schäfer-Korting M; Knauf H; Mutschler E; Just H
    Eur J Clin Pharmacol; 1985; 29(4):461-5. PubMed ID: 4092726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of carteolol on renal function in healthy subjects and patients with hypertension.
    Tabei K; Furuya H; Asano Y; Hosoda S
    Eur J Clin Pharmacol; 1989; 36(1):83-6. PubMed ID: 2917595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Cytembena in chronic renal impairment.
    Schück O; Grafnetterová J; Sotorník I
    Neoplasma; 1976; 23(2):161-70. PubMed ID: 947088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function.
    Webb DB; Roberts DE; Williams JD; Asscher AW
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():83-7. PubMed ID: 3804907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza vaccination of patients with glomerular diseases. Effects on creatinine clearance, urinary protein excretion, and antibody response.
    Pabico RC; Douglas RG; Betts RF; McKenna BA; Freeman RB
    Ann Intern Med; 1974 Aug; 81(2):171-7. PubMed ID: 4846107
    [No Abstract]   [Full Text] [Related]  

  • 8. Human Tamm-Horsfall glycoprotein: urinary and plasma levels in normal subjects and patients with renal disease determined by a fully validated radioimmunoassay.
    Thornley C; Dawnay A; Cattell WR
    Clin Sci (Lond); 1985 May; 68(5):529-35. PubMed ID: 3979015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of hydrochlorothiazide in relation to renal function.
    Niemeyer C; Hasenfuss G; Wais U; Knauf H; Schäfer-Korting M; Mutschler E
    Eur J Clin Pharmacol; 1983; 24(5):661-5. PubMed ID: 6873147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of renal disease on the pharmacokinetics of diethylcarbamazine in man.
    Adjepon-Yamoah KK; Edwards G; Breckenridge AM; Orme ML; Ward SA
    Br J Clin Pharmacol; 1982 Jun; 13(6):829-34. PubMed ID: 7093114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies on kallikrein activity in diabetic patient with hypertension caused by nephropathy].
    Kunii N
    Nihon Jinzo Gakkai Shi; 1989 Jan; 31(1):39-48. PubMed ID: 2746999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
    Graefe-Mody U; Friedrich C; Port A; Ring A; Retlich S; Heise T; Halabi A; Woerle HJ
    Diabetes Obes Metab; 2011 Oct; 13(10):939-46. PubMed ID: 21672124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of serum and urinary neopterins in patients with chronic renal disease.
    Godai K; Uemasu J; Kawasaki H
    Clin Nephrol; 1991 Sep; 36(3):141-6. PubMed ID: 1934670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of renal function on risedronate pharmacokinetics after a single oral dose.
    Mitchell DY; St Peter JV; Eusebio RA; Pallone KA; Kelly SC; Russell DA; Nesbitt JD; Thompson GA; Powell JH
    Br J Clin Pharmacol; 2000 Mar; 49(3):215-22. PubMed ID: 10718776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excretion and metabolism of reserpine in renal failure.
    Zsotér TT; Johnson GE; DeVeber GA; Paul H
    Clin Pharmacol Ther; 1973; 14(3):325-30. PubMed ID: 4698561
    [No Abstract]   [Full Text] [Related]  

  • 16. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function.
    Wu MJ; Ing TS; Soung LS; Daugirdas JT; Hano JE; Gandhi VC
    Clin Nephrol; 1982 Jan; 17(1):19-23. PubMed ID: 7035042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment.
    Mangione A; Boudinot FD; Schultz RM; Jusko WJ
    Antimicrob Agents Chemother; 1982 Mar; 21(3):428-35. PubMed ID: 6213190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractional oxalate clearance in subjects with normal and impaired renal function.
    Boer P; Prenen JA; Koomans HA; Dorhout Mees EJ
    Nephron; 1985; 41(1):78-81. PubMed ID: 4033845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
    Nilsen OG; Saltvedt E; Walstad RA; Marstein S
    Am J Med; 1992 Apr; 92(4A):38S-40S. PubMed ID: 1316068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracerebral penetration of carteolol hydrochloride in rats.
    Kudo S; Umehara K; Abe Y; Furukawa M; Odomi M
    Psychopharmacology (Berl); 1997 Jun; 131(4):388-93. PubMed ID: 9226741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.